Effect of methamphetamine on cytochrome P450 activity

Xenobiotica

Volumn 37, Issue 12, 2007, Pages 1355-1366

  Dostalek, M ^a,c   Jurica, J ^a   Pistovcakova, J ^a   Hanesova, M ^a   Tomandl, J ^a   Linhart, I ^b   Sulcova, A ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interactions; Isolated perfused rat liver; Methamphetamine; P450 induction; P4502C6

Indexed keywords

4 HYDROXYDICLOFENAC; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2D; DEXTROMETHORPHAN; DICLOFENAC DERIVATIVE; METHAMPHETAMINE; MIDAZOLAM; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; ENZYME ACTIVITY; ENZYME METABOLISM; IN VIVO STUDY; ISOLATED LIVER; LIVER METABOLISM; LIVER PERFUSION; MALE; NONHUMAN; PROTEIN FUNCTION; RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DICLOFENAC; EXCITATORY AMINO ACID ANTAGONISTS; HYPNOTICS AND SEDATIVES; HYPOGLYCEMIC AGENTS; KINETICS; LIVER; MALE; METHAMPHETAMINE; MIDAZOLAM; PERFUSION; RATS; RATS, WISTAR; STEROID 21-HYDROXYLASE; TOLBUTAMIDE;

RATTUS;

EID: 36348972231     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701652877     Document Type: Article

References (48)

1. Agrawal AK, Shapiro BH. 2003. Constitutive and inducible hepatic P450 isoforms in senescent male and female rats and response to low-dose phenobarbital. Drug Metabolism and Disposition 31(5):612-619.
2. Allen TS, Kiser WO. 1987. Methamphetamine from ephedrine: 1 Chloroephedrine andaziridines. Journal of Forensic Sciences 32(12):953-962.
3. Anglin MD, Burke C, Perrochet B, Stamper E, Wud-Noursi S. 2000. History of the methamphetamine problem. Journal Psychoactive Drugs 32(2):137-141.
4. Anzenbacher P, Anzenbacherova E. 2001. Cytochrome P450 and metabolism of xenobiotic. Cellular and Molecular Life Sciences 58(5-6):737-747.
5. Baba T, Yamada H, Oguri K, Yoshimura H. 1988. Participation of cytochrome P-450 isozymes in N-demethylation, N-hydroxylation and aromatic hydroxylation of methamphetamine. Xenobiotica 18(5):475-484.
6. Barr AM, Panenka WJ, MacEwa GW, Thorton AE, Lang DJ, Honer WG, Lemonte T. 2006. The need for speed: an update on methamphetamine addiction. Journal of Neuropsychiatry and Clinical Neurosciences 31(5):301-131.
7. Caldwell J, Dring LG, Williams RT. 1972. Metabolism of (14 C) methamphetamine in man, the guinea pig and the rat. Biochemical Journal 129(1):11-22.
8. Cantrell TS, John B, Johnson L, Allen AC. 1988. A study of impurities found in methamphetamine synthesized from ephedrine. Forensic Science International 39(2-3):39-53.
9. Cribb AE, Spielberg SP, Griffin GP. 1995. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metabolism Disposition 23(3):406-414.
10. Derlet RW, Heischober B. 1990. Methamphetamine Stimulant of the 1.990s? Western Journal of Medicine 153(6):625-628.
11. Dostalek M, Hadasova E, Hanesova M, Pisvotcakova J, Sulcova A, Jurica J, Tomandl J, Linhart I. 2005a. Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats. European Journal of Drug Metabolism and Pharmacokinetics 30(3):195-201.
12. Dostalek M, Jurica J, Janostikova E, Zahradnikova L. (2006). Pharmacokinetics. Prague: Grada.
13. Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcova A, Hadasova E. 2005b. Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sciences 78(3):239-244.
14. Edmunds-Ogbuokiri T. 2003. How common illicit substances interact with antiretroviral agents. HIV Clinician 1.5(1):6-7.
15. Ernest CS, Hall SD, Jones DR. 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. The Journal of Pharmacology and Experimental Therapeutics 3.12(2):583-591.
16. Gilman AG, Rall TW, Nies AS, Taylor P, editors. 1990. Goodman and Gillman's the pharmacological basis of therapeutics, 8th edn. New York, NY: Pergamon.
17. Goldstein DJ, Ramper DJ, Potvin JH, Masica DN, Beasley CM. 1993. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Journal of Clinical Psychiatry 54(8):309-316.
18. Greenway F, Herber D, Raum W, Herber D, Morales D, Morales S. 1999. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obesity Research 7(4):370-398.
19. Guengerich FP. 1995. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanisms and biochemistry. New York, NY: Plenum. pp 473-535.
20. Guengerich FP. 1997a. Comparisons on catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions 106(3):161-182.
21. Guengerich FP. 1997b. Role of cytochrome P450 in drug-drug interactions. Advances in Pharmacology 43:7-35.
22. Hales G, Roth G, Smith D. 2000. Possible fatal interaction between protease inhibitors and methamphetamine. Antiviral Therapy 5(1):1-19.
23. Hoen PA, Bijsterbosch MK, Van Berkel TJ, Vermeulen NP, Commandeur JN. 2001. Midazolam is a phenobarbital-like cytochrome p450 inductor in rats. Journal of Pharmacology and Experimental Therapeutics 299(3):921-927.
24. Kiorbe E. 1965. Drug therapy of epilepsy. Preparations II. Nordisk Medicin 73:291-293.
25. Kobayashi K, Urashima K, Shimada N, Chiba K. 2002. Substrate specifity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed system of the rat. Biochemical Pharmacology 63(5):889-896.
26. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblath DJ. 2002. In vitro, pharmacokinetic and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics 302(3):1228-1237.
27. Lau CE, Ma F, Wang Y, Smith C. 1996. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology 126(3):241-248.
28. Logothetis J. 1959. Methamphetamine sulfate in the treatment of nocturnal epileptic seizures. Minnesota Medicine 42(3):248-249.
29. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. 2000. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicology Letters 112-113:133-142.
30. Nebert DW, McKinnon RA. 1994. P450: evolution and functional diversity. Progress in Liver Diseases 12:63-97.
31. Nelson DR. 1999. Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 369(1):1-10.
32. Nelson DR, Koymans L, Katamaki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6(1):1-42.
33. Newton TF, Roache JD, De La Garza II R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. 2005. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 182(3):426-435.
34. Newton TF, Roache JD, De La Garza II R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. 2006. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31(7):1537-1544.
35. Noda Y, Nabeshima Y. 1996. Behavioral assessment of neuroleptics (3) - schizophrenia negative symptoms-like model induced by PCP. Japanese Journal of Psychopharmacology 16(4):123-128.
36. Omiecinski CJ, Hassett C, Costa P. 1990. Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Molecular Pharmacology 38(4):462-470.
37. Patel J, Buddha B, Dey S, Pal D, Mitra AK. 2004. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. American Journal of Therapeutics 11(4):262-277.
38. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH. 2003. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. Journal of Analytical Toxicology 27(8):552-559.
39. Phillips TR, Bilaud JN, Henriksen SJ. 2004. Methamphetamine and HIV-1: potential interactions and the use of the FIV/cat model. Journal of Psychopharmacology 14(3):244-250.
40. Reback CJ, Larkins S, Shoptaw S. 2003. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 15(1):775-785.
41. Rege B, Carter KM, Sarkar MA, Kellogg GE, Soine WH. 2002. Irreversible inhibition of CYP2D6 by (-)-chloroephedrine, a possible impurity in methamphetamine. Drug Metabolism and Disposition 30(12):1337-1343.
42. Semple SJ, Patterson TL, Grant I. 2002. Motivations associated with methamphetamine use among HIV + men who have sex with men. Journal of Substance Abuse Treatment 22(3):149-156.
43. Skinner HF. 1990. Methamphetamine synthesis via hydriodic acid/red phosphorous reduction of ephedrine. Forensic Science International 48(2):123-134.
44. Smith D, Hales D, Roth N, Law M, Ray J, Druett J, Mitchell J, Mills G, Dooing N, Franklin R. 2001. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clinical Trials 2(2):97-107.
45. Tanaka K, Ohmori T, Inoue T. 1992. Analysis of impurities in illicit methamphetamine. Forensic Science International 56(1):157-165.
46. Williams MT, Moran MS, Vorhess CV. 2004. Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats. International Journal of Developmental Neuroscience 22(5-6):273-283.
47. Wu D, Otto SV, Inaba T, Kalow W, Sallers EM. 1997. Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology 53(11):1605-1612.
48. Zive JL, Leonard J. 2005. Creating a friendly environment for your HIV medications The effect of interactions. Positively Aware 32:16-21.